In response to the official approval of recanemab, a new drug that directly acts on the causative agent of Alzheimer's disease, Chuikyo = Central Social Insurance Medical Council confirmed its policy of calculating the price with the aim of applying public medical insurance by the end of December.
At its general meeting on the 1th, Chuikyo began discussions on insurance coverage and price calculation for recanemab, a new treatment for Alzheimer's disease, one of the causes of dementia, jointly developed by Eisai, a major Japan pharmaceutical company, with Biogen of the United States.
In the United States, the average annual price per person is set at about 27.1 million yen, and the Ministry of Health, Labor and Welfare explained that the annual market size may exceed 390 billion yen depending on the number of patients and other factors.
In response to this, members expressed the opinion that ▽ there were high expectations for the effects of the drug and called for insurance coverage after ensuring safety, while ▽ "Since the burden on insurance finances is extremely large,
the target patients and the duration of administration should be appropriate."
We also confirmed our policy of calculating the price, aiming to make it covered by insurance by the end of December, which is 1500 days after the official approval.
Regarding a new treatment for Alzheimer's disease, Eli Lilly, a major American pharmaceutical company, announced on March 90 that it has filed an application for approval in Japan for donanemab, a new drug for Alzheimer's disease under development, in Japan.